Characteristic | |
Age (years)* | 59.9 (11.4) |
Female (%) | 60 |
Duration of RA (years)* | 10.6 (9) |
ELISA IgM-RF positive (%) | 77 |
Erosive changes on x ray (%) | 75 |
Weeks between entry in the placebo controlled study and flare† | 27 (3 to 52) |
Number of patients with severe flare | 24 |
Data shown as mean (SD)* and median (range)†.